Associated Genetic Biomarkers
Nuclear receptor co-activator 2 (NCOA2) is a gene that encodes a protein that functions as a nuclear receptor co-activator - a protein that helps nuclear hormone receptors function properly. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and pleural cancer.
NCOA2 is altered in 0.28% of all cancers with breast invasive ductal carcinoma, conventional glioblastoma multiforme, lung adenocarcinoma, colon adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations .
The most common alterations in NCOA2 are NCOA2 Fusion (0.04%), NCOA2 Q82H (0.18%), NCOA2 A1166T (0.77%), NCOA2 D824E (0.77%), and NCOA2 E594dup (0.15%) .
NCOA2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains NCOA2 status as an inclusion criterion, 1 is phase 2 (1 open).
The most frequent alteration to serve as an inclusion eligibility criterion is HEY1-NCOA2 Fusion .
Significance of NCOA2 in Diseases
Mesenchymal Chondrosarcoma +
NCOA2 is altered in 60.0% of mesenchymal chondrosarcoma patients .
NCOA2 is an inclusion criterion in 1 clinical trial for mesenchymal chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains NCOA2 status and mesenchymal chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.